Tempus AI Inc ( TEM ) shares are moving higher Monday after the company introduced a new program to monitor immunotherapy response for patients with advanced cancer.

What Happened: Tempus has announced xM for treatment response monitoring, which is a liquid biopsy assay aimed at detecting molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors.

The new array for monitoring immunotherapy response is currently only available for research use, but clinical availability is expected later this year.

xM for treatment response monitoring is designed to quantify changes in circulating tumor DNA longitudinally from a blood sample by leveraging a multi-parametric algorithm. The company will present new data on xM for treatment response monitoring at the 2025 American Society of Clinical Oncology annual meeting.

“We’re excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies,” said Halla Nimeiri, chief development officer at Tempus AI ( TEM ).

“With xM for TRM, clinicians can detect molecular response to ICI prior to six weeks into treatment, enabling them to stay ahead of disease progression and optimize therapeutic strategies.”

How To Buy TEM Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Tempus AI's ( TEM ) case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

TEM Price Action: Tempus AI ( TEM ) shares were up 17.4% at $64.80 at the time of publication Monday, according to Benzinga Pro.

Read Next:

Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is ‘Cash Out King’ 

Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value